Financial results of the Company for the quarter and nine months ended on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Standalone revenue from operations jumped 120% year-on-year in Q3 FY26 to Rs 2,162.55 lakhs and rose 156% YoY for the nine-month period to Rs 5,404.25 lakhs, led by merchandise sales. Despite the strong top-line, standalone net profit fell sharply to Rs 1.98 lakhs in Q3 (vs Rs 45.74 lakhs a year ago) and Rs 11.91 lakhs for 9M (vs Rs 161.33 lakhs), as employee costs more than tripled and expenses surged. On a consolidated basis, which now includes the newly consolidated subsidiary Neuro and Spine Associates (acquired April 2025), the company swung to a net loss of Rs 1,153 lakhs for 9M FY26 (vs a profit of Rs 126.59 lakhs earlier). The auditor issued an unmodified (clean) limited review report. The board also appointed SKSM & Associates as the new internal auditor for FY26-27 and disclosed the incorporation of a new US subsidiary, eYantra Ventures Inc, in Delaware.
Strong revenue growth is being offset by a dramatic slump in profitability, both on a standalone basis (where margins have collapsed) and especially at the consolidated level (driven by losses from the recently acquired healthcare subsidiary). Shareholders should note the consolidated bottom-line has turned meaningfully negative, which is a key concern even as the company expands into new business lines.